INO
HEALTHCAREInovio Pharmaceuticals Inc
AI Insight
What's Moving INO Today?
No stock-specific AI insight has been generated for INO yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.03$2.98
$1.12
Fundamentals
Market Cap$91M
P/E Ratio—
EPS$-1.58
Dividend Yield—
Dividend / Share—
ROE-296.4%
Profit Margin—
Debt / Equity—
Trading
Volume824K
Avg Volume (10D)—
Shares Outstanding82.3M
INO News
39 articles- INOVIO to Participate in Upcoming Scientific and Investor ConferencesYahoo Finance·May 28, 2026
- Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review AdvancesMarketbeat·May 25, 2026
- INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia TrialStocktwits·May 21, 2026
- Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in ChinaYahoo Finance·May 21, 2026
- Investigation Alert: Investors who hold shares of InovioopenPR.com·May 15, 2026
- INOVIO (NASDAQ: INO) details Q1 loss and INO-3107 accelerated FDA reviewStock Titan·May 14, 2026
- Inovio Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 14, 2026
- Inovio Pharmaceuticals Inc (INO) Q1 2026 Earnings Call Highlights: Progress and Challenges in ...Yahoo Finance·May 14, 2026
- Full Transcript: Inovio Pharmaceuticals Q1 2026 Earnings CallYahoo Finance·May 13, 2026
- INOVIO Reports First Quarter 2026 Financial Results and Recent Business HighlightsYahoo Finance·May 13, 2026
- Moderna Stock Loses Steam. Hantavirus Trade Fizzles as Officials Dismiss Pandemic Risk.Yahoo Finance·May 11, 2026
- INOVIO to Report First-Quarter Results on May 13MyChesCo·May 10, 2026
- INO Stock Jumps As Inovio Showcases DNA Medicine Datawww.timothysykes.com·May 10, 2026
- INO Rallies As Inovio Showcases DNA Medicine ProgressTimothy Sykes·May 9, 2026
- INOVIO to Participate in Upcoming Scientific ConferencesYahoo Finance·May 8, 2026
- ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales GrowthYahoo Finance·May 7, 2026
- Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpYahoo Finance·May 7, 2026
- RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/YYahoo Finance·May 7, 2026
- RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal EffectYahoo Finance·May 6, 2026
- INOVIO to Report First Quarter Financial Results on May 13, 2026Yahoo Finance·May 1, 2026
- Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/YYahoo Finance·May 1, 2026
- Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?Yahoo Finance·Apr 30, 2026
- Vertex Gears Up to Report Q1 Earnings: What Investors Can ExpectYahoo Finance·Apr 28, 2026
- CRISPR Therapeutics to Report Q1 Earnings: Is a Beat in the Cards?Yahoo Finance·Apr 27, 2026
- INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer StudyYahoo Finance·Apr 23, 2026
- Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers – INOGlobeNewswire Inc.·Apr 7, 2026
- DEADLINE ALERT for PSFE, INO, KD: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class ActionsGlobeNewswire Inc.·Apr 7, 2026
- Bragar Eagel & Squire, P.C. Urgently Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inovio Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before April 7thGlobeNewswire Inc.·Apr 6, 2026
- Shareholders that lost money on Atara Biotherapeutics, Inc.(ATRA) should contact Levi & Korsinsky about pending Class Action - ATRAGlobeNewswire Inc.·Apr 6, 2026
- UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages uniQure N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QUREGlobeNewswire Inc.·Apr 6, 2026
- INO FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INOGlobeNewswire Inc.·Apr 6, 2026
- Deadline Alert: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlobeNewswire Inc.·Apr 3, 2026
- INO FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INOGlobeNewswire Inc.·Apr 2, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TCOMGlobeNewswire Inc.·Apr 2, 2026
- ROSEN, THE FIRST FILING FIRM, Encourages Kyndryl Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – KDGlobeNewswire Inc.·Mar 30, 2026
- INOVIO DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INOGlobeNewswire Inc.·Mar 30, 2026
- Bronstein, Gewirtz & Grossman LLC Urges Inovio Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc.·Mar 30, 2026
- INO DEADLINE ALERT: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INOGlobeNewswire Inc.·Mar 24, 2026
- Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc.and Certain Officers – INOGlobeNewswire Inc.·Mar 24, 2026
All 39 articles loaded
Price Data
Open$1.09
Previous Close$1.11
Day High$1.16
Day Low$1.09
52 Week High$2.98
52 Week Low$1.03
52-Week Range
$1.03$2.98
$1.12
Fundamentals
Market Cap$91M
P/E Ratio—
EPS$-1.58
Dividend Yield—
Dividend / Share—
ROE-296.4%
Profit Margin—
Debt / Equity—
Trading
Volume824K
Avg Volume (10D)—
Shares Outstanding82.3M
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA drugs to treat and protect people from diseases associated with the human papillomavirus (HPV), cancer, and infectious diseases.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—